Abstract library

91 results for "Ali".
#1114 CT Evaluation of Gastric Neuroendocrine Neoplasm Based on WHO 2010 Classification
Introduction: The 2010 WHO classification classifies GEP-NEN into grade 1, 2 and 3.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Ying Li
Authors: Li Y, Li Z W, Tang L, Cao K, ...
#1290 PD-L1 Expression is Associated with Grade of Neuroendocrine Tumors
Introduction: Neuroendocrine neoplasms are divided into well-differentiated neuroendocrine tumors (WDNETs) and poorly differentiated neuroendocrine carcinomas (PDNECs).The correlation between Gastroenteropancreatic Neuroendocrine Neoplasms (GEPNENs) and immunocheck point molecule-PD-L1 is still unclear now.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: Professor Zhongwu Li
Authors: Li Z, Leng J, Wang H, Li S, ...
#1378 Evaluation of CT Prognostic Factors of Neuroendocrine Liver Metastasis Treated with Transcatheter Arterial Embolization
Introduction: TAE has been shown to be effective in the management of metastatic NET.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Ying Li
Authors: Li Y, Liu P, Cao K, Li J, ...
#1429 Evaluate the Accuracy of Pathological Diagnosis on Biopsy Specimens from Gastrointestinal Neuroendocrine Tumors
Introduction: Gastrointestinal neuroendocrine neoplasms (GI-NENs) is a highly heterogeneous tumor. The accuracy of pathological diagnosis on the biopsy is crucial for GI-NENs but rarely investigated
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: Doctor Li Sun
Authors: Sun L, Li S, Li J, Lu M, ...
#1473 Long-term Outcomes of Colorectal Neuroendocrine Tumors: A Sub Group Analysis of 29 G3 Cases According to the 2010 WHO Classification
Introduction: Colorectal neuroendocrine tumors (NETs) are a group of heterogenous neoplasm.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Jiahua Leng
Authors: Leng J, Li Z W, Li Y, Chen Z S, ...
#1660 The Clinicopathological Characteristics of Small Intestinal Neuroendocrine Neoplasms: A Multicenter Retrospective Study from China
Introduction: Small intestinal NEN (SI-NEN) is much rarer in Asian countries. Hence, the clinicopathological characteristics of SI-NEN are still unknown in Asian population.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Jie Chen
Authors: Chen L, Zhou L, Zhang M, Shang L, ...
#1697 An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)
Introduction: Patients (pts) with advanced neuroendocrine tumors (NETs) who have failed sunitinib or everolimus have limited treatment options. Sulfatinib, a novel kinase inhibitor targeting tumor angiogenesis and immune evasion, has shown encouraging anti-tumor activity in patients with advanced NETs in a phase I study.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Jian Ming Xu
Authors: Xu J, Li J, Bai C M, Xu N, ...
Keywords: sulfatinib, net, orr, pfs
#2125 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: 400 Cases of Multicenter Retrospective Analysis
Introduction: Definitions of Type 3 gastric NEN (g-NEN) in ENETS Guidelines 2012 and 2016 are ambiguous and controversial, so Four-type classification has been proposed in China.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Huang-Ying Tan
Authors: Li Y L, Zhang P, Qiu X D, Li X K, ...
#2914 Safety Profile and Adverse Events of Special Interest for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial
Introduction: The previously reported SANET-ep trial (NCT02588170) demonstrated surufatinib significantly improves progression-free survival (PFS) in patients (pts) with advanced extrapancreatic neuroendocrine tumors (epNETs) compared to placebo; median PFS (9.2 vs. 3.8 months; HR = 0.334, 95% CI 0.223 to 0.499, p<0.0001).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Jie Li
Authors: Li J, Xu J, Zhou Z, Bai C, ...
#2177 Assessment of Quality of Life in Chinese Patients with Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Descriptive analysis on the QOL in patients(pts) with GEP-NET are rare.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Huang-Ying Tan
Authors: Liu Q, Li Y L, Qiu X D, Li X K, ...